ARCHIVES

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

Harold Varmus Addresses the NCI Board of Scientific Advisors

March 8, 2013

In Brief: Columbia University Double Lab Space; GM Cancer Awards to Suit, Folkman, Nurse

June 6, 1997

Letter: The Lesson From Dana-Farber

July 28, 1995

In Brief: Strohl Leads Oncology Nursing Society; ONS Seeks Nominees For Consumer Panel

June 4, 1999

Guest Editorial: The Supreme Court Decision on the ACA and What It Can Mean to Oncology

June 29, 2012

NCI Advisory Group, Other Cancer Meetings For April, May

March 26, 1976